← Back to Clinical Trials
Recruiting NCT06944392

NCT06944392 Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06944392
Status Recruiting
Phase
Sponsor Northwestern University
Condition Overactive Bladder (OAB)
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-04-11
Primary Completion 2026-08-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Pumpkin Seed Extract

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-04-11 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a pilot study to assess using validated outcome measures how ingesting pumpkin seed oil extract supports patient bladder function in a United States population.

Eligibility Criteria

Inclusion Criteria: * All patients evaluated at Northwestern's IPHP who report bladder function consistent with overactive bladder (urinary urgency, with or without urinary frequency more than 8 times daily or nocturia, with or without urgency urinary incontinence) at their index visit, who are also willing to use a dietary supplement and not initiate additional behavioral, medication or procedural treatment for 12 weeks following pumpkin seed oil extract initiation. Exclusion Criteria: * Patients with any of the following will be excluded from the study: * Use of other supplements that contain pumpkin seed oil * ≥Stage 3 pelvic organ prolapse * Urinary post-void residual ≥150cc * Culture-proven urinary tract infection at time of study enrollment * Recurrent urinary tract infection * Neurogenic bladder * Abdominal or pelvic malignancy * Initiation of new overactive bladder medications or supplements during study period or in the 3 months immediately preceding study enrollment * History of surgery in the past 12 months for pelvic organ prolapse, stress urinary incontinence, urgency urinary incontinence, or fecal or flatal incontinence * Patient's primary language is not English

Contact & Investigator

Central Contact

Julia Geynisman-Tan, MD

✉ Julia.Geynisman-Tan@nm.org

📞 312-926-9929

Frequently Asked Questions

Who can join the NCT06944392 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Overactive Bladder (OAB). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06944392 currently recruiting?

Yes, NCT06944392 is actively recruiting participants. Contact the research team at Julia.Geynisman-Tan@nm.org for enrollment information.

Where is the NCT06944392 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT06944392 clinical trial?

NCT06944392 is sponsored by Northwestern University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology